BJ

Brenda Juliette Nazareth Menezes

Active Director Director DIN 01126236
DIN 01126236 First appointment Apr 2007 Primary industry Financial Services
Unlock full profile Investments · shareholding · contact details
Current companies 6 active board seats
Total affiliations 6 Since Apr 2007
Shareholding value •••• Premium profile

About Brenda Juliette Nazareth Menezes

Data last updated:

Brenda Juliette Nazareth Menezes is a Director at Cfl Pharmaceuticals Limited (since 2013), Director at Menezes Remedies Limited (since 2017) and Director at Menezes Pharmaceuticals Limited (since 2013), and holds 3 more current directorships. The companies operate in Financial Services, Pharma and Agriculture. The 5 current companies with reported revenue have a combined latest revenue of ₹237 Cr; the largest is Cfl Pharmaceuticals Limited at ₹202 Cr (FY 2025).

DIN 01126236
Primary Designation Director
Industry Financial Services
First Appointment 19 Apr 2007
Oldest Company Age 45 yrs
Largest company Cfl Pharmaceuticals Limited · ₹202 Cr (FY 2025)
Combined revenue ₹237 Cr across 5 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cfl Pharmaceuticals Limited U24246GA1981PLC000465
Director30 Oct 20131981₹202 Cr (FY 2025)Active
Menezes Remedies Limited U52311GA1996PLC002041
Director09 Jan 20171996₹17.69 Cr (FY 2025)Active
Menezes Pharmaceuticals Limited U24232GA1996PLC002040
Director30 Oct 20131996₹17.15 Cr (FY 2025)Active
Cosme Bio-Tech Private Limited U31200GA1997PTC002440
Director01 Oct 20141997₹50.3 Lakh (FY 2025)Active
Director10 Apr 20131992₹50,408 (FY 2017)Active
Director19 Apr 20071996Active

Directorship timeline

Open interactive timeline →
Menezes Pharmaceuticals Limited
Cfl Pharmaceuticals Limited
Frederick Electro Devices Private Limited
Cosme Bio-Tech Private Limited
Premium access

Shareholding and investment profile for Brenda Juliette Nazareth Menezes

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Brenda Juliette Nazareth Menezes

Brenda Juliette Nazareth Menezes currently holds 6 directorships: Cfl Pharmaceuticals Limited (Director, since 30 Oct 2013, revenue ₹202 Cr (FY 2025)); Menezes Remedies Limited (Director, since 09 Jan 2017, revenue ₹17.69 Cr (FY 2025)); Menezes Pharmaceuticals Limited (Director, since 30 Oct 2013, revenue ₹17.15 Cr (FY 2025)); Cosme Bio-Tech Private Limited (Director, since 01 Oct 2014, revenue ₹50.3 Lakh (FY 2025)); Frederick Electro Devices Private Limited (Director, since 10 Apr 2013, revenue ₹50,408 (FY 2017)); and 1 more.

Brenda Juliette Nazareth Menezes was first appointed on 19 Apr 2007 as Director at Cosme Stocks And Credits Private Limited. The most recent appointment on record is 09 Jan 2017 at Menezes Remedies Limited.

The 5 current companies of Brenda Juliette Nazareth Menezes that report revenue have a combined latest revenue of ₹237 Cr: Cfl Pharmaceuticals Limited ₹202 Cr (FY 2025); Menezes Remedies Limited ₹17.69 Cr (FY 2025); Menezes Pharmaceuticals Limited ₹17.15 Cr (FY 2025); Cosme Bio-Tech Private Limited ₹50.3 Lakh (FY 2025); Frederick Electro Devices Private Limited ₹50,408 (FY 2017).

The current boards of Brenda Juliette Nazareth Menezes's companies include Christine Stephanie Menezes (Cfl Pharmaceuticals Limited), Maryann Veronica Menezes (Cfl Pharmaceuticals Limited), Peter Mark Menezes (Menezes Remedies Limited), Sandesh Anant Kamat Bambolkar (Cosme Bio-Tech Private Limited), Andre Jose Joao De Menezes (Cosme Stocks And Credits Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available